Aptose Biosciences — Investor Presentation (July 2022)
25 slides from Aptose Biosciences's investor presentation, Jul 20, 2022
Slide 1: Aptose Corporate Presentation
P R E C I S I O N O N C O L O G Y F O R T H E R A P I E S O F T O M O R R O W Aptose Corporate Presentation NASDAQ: APTO TSX: APS J u l y 2 0 2 2
Slide 2: Disclosure
Disclosure 2 This presentation does not, and is not intended to, constitute or form part of, and should not be construed as, an offer or invitation for the sale or purchase of, or a solicitation of an offer to purchase, subscribe for or otherwise acquire, any securities, businesses and/or assets of
Slide 3: Aptose Biosciences: Investor highlights
Aptose Biosciences (NASDAQ: APTO) 3 Building a pipeline of “Best in Class” targeted therapies to serve cancer patients with hematologic malignancies • Precision therapeutics designed to provide single agent efficacy and to be used in combination with conventional anti - cancer therapies and other ta
Slide 4: Clinical Stage Pipeline of Differentiated Myeloid Kinase Inhibitors
Aptose Biosciences: Clinical Stage Pipeline of Differentiated Myeloid Kinase Inhibitors 4 LUXEPTINIB (CG - 806) dual lymphoid and myeloid kinase inhibitor High Value Targets Activity in Ill Patients Improved Formulation | B - cell cancers, AML/MDS and inflammation: BTK, FLT3, LCK, LYN, Others | Diff
Slide 5: Aptose Leadership Team: Multifaceted Expertise in Therapeutic Development
Aptose Leadership Team : Multifaceted Expertise in Therapeutic Development William G. Rice, PhD Chairman, President & Chief Executive Officer Philippe Ledru Sr. VP & Chief Commercial Officer Rafael Bejar, MD, PhD Sr. VP & Chief Medical Officer Fletcher Payne Sr. VP & Chief Financial Officer 5
Slide 6: Aptose SAB: Distinguished Opinion Leaders with Deep Oncology Expertise
Aptose SAB : Distinguished Opinion Leaders with Deep Oncology Expertise 6 Brian J. Druker, MD Pioneer in the field of precision medicine Key Role in development of Gleevec - the first targeted kinase inhibitor for cancer Member, National Academy of Medicine, National Academy of Sciences & American A
Slide 7: HM43239 Oral, Daily, Myeloid Kinase Inhibitor
7 HM43239 “239” Ora l , Da i l y, Mye l o i d K i na se I nhi b i tor
Slide 8: AML in the US: Continued Unmet Need for More Effective and Safe Therapies
AML in the US : Estimated 20,240 new cases and 11,400 deaths in 2021 Continued Unmet Need for More Effective and Safe Therapies 8 Epidemiology US (2021) EU5 (2020) Japan (2021) China (2020) Leukemia Incidence 3 61,090 1 51,820 3 14,600 7 85,400 AML Incidence 20,240 2 16,580 3a 6,570 7c 31,430 3b 5 -
Slide 9: Effective and Well Tolerated Targeted Agent Proven Broad Clinical Activity in AML
HM43239 Effective and Well Tolerated Targeted Agent Proven Broad Clinical Activity in AML Patients to Treat Significant Unmet Needs HM43239 AML Kinase Inhibitor Single Agent CRs CR and No DLT at 3 dose levels Broad Therapeutic Window No drug - related SAE, QTc toxicities, or CK increases Validated A
Slide 10: Emerging Clinical Data Support HM43239 as Potential Superior Therapy
Emerging Clinical Data Support HM43239 as Potential Superior Therapy 10
Slide 11: Phase 1/2 Study in R/R AML: Ongoing Dose Escalation & Dose Exploration
HM43239 Phase 1/2 Study in R/R AML: Ongoing Dose Escalation & Dose Exploration 11 PART A : DOSE ESCALATION PART B : DOSE EXPLORATION Cohort 6 200 mg QD Ongoing Cohort 5 160 mg QD Completed Cohort 4 120 mg QD Completed Cohort 3 80 mg QD Completed Cohort 2 40 mg QD Completed Cohort 1 20 mg QD Complete
Slide 12: Safety and Efficacy Data Revealed a Broad Therapeutic Window as a Single Agent
HM43239 Safety and Efficacy Data Revealed a Broad Therapeutic Window as a Single Agent in R/R AML Patients 12 CONFIDETIAL • Safety Profile Favorable to Date ― No drug related SAE, deaths, or AE of elevated CK (creatine kinase) ― No drug related AE of QT prolongation – No observed relation between
Slide 13: Diversity of R/R AML Patients Who Achieved a Clinical Response
HM43239 Diversity of R/R AML Patients Who Achieved a Clinical Response to Date in Phase 1/2 Study Abbreviation: CR, complete response; CRi, complete response with incomplete hematologic recovery; CRp, complete response with incomplete platelet recovery; HSCT, hematopoietic stem cell transplantation;
Slide 14: AML Patients with Best Clinical Responses to Date
HM43239 AML Patients with Best Clinical Responses to Date Observed 7 CRc and 1 PR in Diverse and Challenging Patient Populations 14 R/R AML FLT3 Mutated FLT3 - ITD FLT3 - ITD FLT3 - ITD Prior Mido/Gilt FLT3 - WT Normal Cytogenetics Abnormal Cytogenetics Abnormal Cytogenetics NRAS RUNX1 KRAS NPM1 DNM
Slide 15: HM43239 Overall Response Rate (CRc + PR) in R/R AML
Abbreviation: CR, complete remission; CRc, composite complete remission; CRp, complete remission with incomplete platelet recovery; CRi, complete remission with incomplete hematological recovery; PR, partial remission. Note: efficacy evaluable patients include all patients with at least 80% drug com
Slide 16: Potential for Accelerated Path Supported by Expansion & Registration Trials
HM43239 Potential for Accelerated Path Supported by Expansion & Registration Trials 16 Current Dose Escalation/Dose Exploration Phase 1/2 Trial in R/R AML Patients — Continue Exploration of Molecular Subgroups (Genotypes) for Potential Fast Track Designations o Expect Continued Dose Exploration at 1
Slide 17: HM43239 Global Dose Expansion Trial Planned to Support Registrational Trials
HM43239 Single Agent FLT3 - Mutated Cohort: ─ Prior FLT3i ─ FLT3i naïve FLT3 - Unmutated Cohort: ─ TP53 MUT /Complex Karyotype ─ Other HM43239 + Venetoclax Combo FLT3 - Mutated Cohort FLT3 - Unmutated Cohort HM43239 Global Dose Expansion Trial Planned to Support Phase 2 Registrational Trials for Acc
Slide 18: Clinical Development Plan Sets the Stage for Broad Commercial Success
Clinical Development Plan Sets the Stage for Broad Commercial Success 18
Slide 19: Safely Delivers Clinical CRs in AML Patients with Diverse Mutations
HM43239: Safely Delivers Clinical CRs in AML Patients with Diverse Mutations Broad Commercial Potential Unlike Any Other Targeted Agent for AML TP53 - Mutated AML IDH - Mutated AML RUNX1 - Mutated AML DNMT3A - Mutated AML FLT3 - Mutated AML RAS - Mutated AML NPM1 - Mutated AML MLL - Mutated AML HM43
Slide 20: TPP: Safe, Oral, Daily, Targeted Agent for Diverse AML Patients
HM43239 TPP : Safe, Oral, Daily, Targeted Agent for Diverse AML Patients 20 Proven Broad Clinical Activity to Deliver Complete Remissions (CRs) in Diverse R/R AML Patients • Genetic diversity (FLT3, TP53, NRAS, KRAS, IDH1, IDH2, MLL, NPM1, PTPN11, DNMT3A, RUNX1, etc.) • FLT3 - unmutated (with comple
Slide 21: Potential Commercial Opportunity in the AML Market
HM43239 Potential Commercial Opportunity in the AML Market AML Patient Population Segment Estimated Treatable Population with HM43239 Estimated Median Duration of Treatment Estimated Peak Market Share (%) US Sales Potential (2035) - USD FLT3(+) RR AML / Prior FLT3i (Gilt) ~ 400 3 months 60% ~$25 mil
Slide 22: Targets Constellation of Kinases Important in AML
Targets Constellation of Kinases Important in AML • Potent inhibitor of myeloid kinases SYK, FLT3 WT/MUT , JAK1/2 and mutant forms of c - KIT associated with transformation and resistance • Potential to treat genetically defined AML patients across multiple lines of therapy & populations • Safety &
Slide 23: Potential Timelines of Value Driving Milestones
HM43239 Potential Timelines of Value Driving Milestones Ph 1/2 Dose Escalation & Exploration Trial Sep Oct Nov Dec 2023 Jan Feb Mar Apr May Jun Jul Sep Oct Nov Dec EHA 2023 • Data Readout for SA & Combo Dose Expansion Trial ─ FLT3 - WT & FLT3+ ─ FLT3+ with prior FLT3i therapy ─ TP53 mutant patients
Slide 24: Aptose Biosciences: Investor highlights
Aptose Biosciences (NASDAQ: APTO) 24 Building a pipeline of “Best in Class” targeted therapies to serve cancer patients with hematologic malignancies • Precision therapeutics designed to provide single agent efficacy and to be used in combination with conventional anti - cancer therapies and other t
Slide 25: Precision Oncology for Therapies of Tomorrow
P R E C I S I O N O N C O L O G Y F O R T H E R A P I E S O F T O M O R R O W We thank our partners, investigators, and investors for helping us bring novel drugs to patients with the greatest need.
Aptose Biosciences — Investor Presentation (July 2022) on 6ix